Outlook therapeutics, inc. (OTLK)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15
OPERATING ACTIVITIES
Net loss

-36,840

-41,384

-34,523

-36,627

-40,618

-37,913

-30,091

-24,265

-21,165

-21,671

-38,849

-43,043

-60,039

-55,536

-53,301

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

2,073

2,714

3,361

3,297

3,286

3,200

3,054

2,900

2,750

2,698

2,692

2,625

2,552

2,470

2,394

0

0

0

Loss on extinguishment of debt

0

0

-

-

-

-

-1,252

0

0

0

-

-

-

-

-

-

-

-

Non-cash interest expense

554

879

1,314

1,429

1,240

1,186

1,315

2,905

4,007

4,453

4,014

2,314

985

151

13

0

0

0

Stock-based compensation

837

800

1,313

1,270

1,536

968

1,985

3,482

5,369

7,997

8,571

10,744

19,197

12,424

12,450

0

0

0

Change in fair value of redemption feature

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrant liability

-2,305

-1,003

-2,438

-3,087

-1,091

-2,605

-1,047

591

-3,223

-4,047

-3,158

0

0

0

-

-

-

-

Impairment of property and equipment

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-20

0

0

0

Prepaid expenses and other current assets

2,944

2,905

3,245

3,625

1,228

677

1,419

277

207

415

-2,607

-211

60

-555

1,533

0

0

0

Other assets

213

224

87

73

-100

-8

-1

-27

-22

-105

-112

-59

-63

-73

-57

0

0

0

Operating lease liability

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

-536

-780

-1,331

-643

428

-25

-6,714

-8,936

-8,155

-7,121

5,727

7,044

-231

806

-5,326

0

0

0

Accrued expenses

61

2,041

-482

-653

140

-524

-1,664

-2,604

-2,884

-2,886

893

-736

2,191

171

1,154

0

0

0

Income taxes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

100

0

0

0

Deferred revenue

-

-

-8,146

-3,049

-3,207

-3,338

-3,057

-187

250

719

1,188

-1,404

-1,596

-1,787

-1,979

0

0

0

Other liabilities

365

260

94

-253

-330

-457

-331

-12

-238

21

135

201

294

382

455

0

0

0

Net cash used in operating activities

-30,005

-29,182

-32,289

-34,767

-32,970

-34,149

-33,039

0

0

0

-

-

-

-

-

-

-

-

INVESTING ACTIVITIES
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-36,364

-39,312

-45,482

0

0

0

Purchase of property and equipment

-

-

437

1,700

1,717

1,942

2,781

1,542

1,450

1,218

292

596

972

882

1,098

0

0

0

Net cash used in investing activities

-

-

-437

-1,700

-1,717

-1,942

-2,781

0

0

0

-

-

-

-

-

-

-

-

FINANCING ACTIVITIES
Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-972

-882

-1,098

0

0

0

Proceeds from the sale of common stock, net of offering costs

-

-

45,964

0

0

0

-

-

-

-

-

-

-

-

16,137

0

0

0

Payment of debt issuance costs

-

-

-

-

-

-

-

-

-

-

40

0

0

0

-

-

-

-

Proceeds from subscriptions receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,280

0

0

0

Proceeds from issuance of Series A convertible preferred stock

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

Proceeds from the sale of senior secured notes and detachable warrants

-

-

-

-

-

-

-

-

-

-

15,000

0

0

0

-

-

-

-

Proceeds from future stock issuance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from exercise of common stock warrants

0

0

-

-

-

-

-

-

-

-

253

0

0

0

-

-

-

-

Payments of finance lease obligations

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of stockholder notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

11,601

0

0

0

Change in restricted cash

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Payments of capital leases obligations

-

-

-

-

-

-

862

895

888

977

991

955

918

894

884

0

0

0

Repayment of debt

1,813

3,302

6,417

6,437

4,692

3,223

127

106

111

128

2,677

3,173

3,323

3,458

1,059

0

0

0

Payment of financing costs

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Net cash provided by financing activities

34,654

30,489

39,025

38,671

28,907

22,482

34,352

0

0

0

-

-

-

-

-

-

-

-

Net decrease in cash

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from related party receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

826

0

0

0

Deconsolidation of Sonnet Biotherapeutics, Inc.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

401

0

0

0

Payment of employee tax withholdings related to the vesting of restricted stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

71

0

0

0

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

34,575

36,690

39,861

0

0

0

Net increase in cash

-

-

-

-

-

-

-

11,656

5,855

11,759

833

-13,415

-2,761

-3,503

-6,719

0

0

0

Supplemental disclosure of cash flow information
Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

0

0

0

Cash paid for interest

1,831

1,498

2,794

2,739

1,766

1,741

109

0

0

0

-

-

-

-

-

-

-

-

Cash paid for income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3

0

0

0

Supplemental schedule of noncash investing activities:
Purchases of property and equipment in accounts payable and accrued expenses

-

-

-

0

0

0

-

0

0

0

-

0

0

0

-

-

-

-

Purchases of property and equipment in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Supplemental schedule of noncash financing activities:
Unsecured notes and accrued interest converted into common stock

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of exchange notes at estimated fair value

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of redemption feature at estimated fair value

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of redeemable common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,463

0

0

0

Issuance of Series B convertible preferred stock upon conversion of senior secured notes, net of unamortized debt discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

11,894

0

0

0

Issuance of Series B convertible preferred stock upon conversion of senior secured notes, net of unamortized debt discount

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Issuance of common and Series A preferred stock to redeemable preferred stockholders and noncontrolling interests upon reincorporation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Reclassification of equity classified stock-based compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

15,118

0

0

0

Change in fair value of convertible senior secured notes warrants recorded as debt discount

-

-

1,466

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Series A-1 convertible preferred stock dividends and related settlement

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Series A and A-1 convertible preferred stock dividends

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Deferred offering costs and common stock issuance costs in accounts payable and accrued expenses

-

-

-

-

0

0

-

-

-

-

630

0

0

0

-

0

0

0

Accrued directors' fees settled in fully vested stock options

-

-

49

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-